SAB Biotherapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Stock-Based Compensation Growth & History (SABS)
SAB Biotherapeutics's stock-based compensation was $5.2M for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.2M | $2.3M | +77.12% |
| 2024 | 2024-12-31 | $2.9M | $518,076 | +21.38% |
| 2023 | 2023-12-31 | $2.4M | −$250,483 | −9.37% |
| 2022 | 2022-12-31 | $2.7M | $359,521 | +15.53% |
| 2021 | 2021-12-31 | $2.3M | $1.0M | +78.68% |
| 2020 | 2020-12-31 | $1.3M | — | — |
SAB Biotherapeutics quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.2M | $6.6M | +1055.75% |
| Q1 2026 | 2026-03-31 | $5.5M | $4.8M | +790.76% |
| Q4 2025 | 2025-12-31 | $3.2M | $2.5M | +370.19% |
| Q3 2025 | 2025-09-30 | $800,913 | −$247,870 | −23.63% |
| Q2 2025 | 2025-06-30 | $627,049 | $25,616 | +4.26% |
| Q1 2025 | 2025-03-31 | $612,951 | −$4,494 | −0.73% |
| Q4 2024 | 2024-12-31 | $674,135 | $137,256 | +25.57% |
| Q3 2024 | 2024-09-30 | $1.0M | $409,537 | +64.07% |
| Q2 2024 | 2024-06-30 | $601,433 | −$43,382 | −6.73% |
| Q1 2024 | 2024-03-31 | $617,445 | $14,665 | +2.43% |
| Q4 2023 | 2023-12-31 | $536,879 | −$91,660 | −14.58% |
| Q3 2023 | 2023-09-30 | $639,246 | $61,043 | +10.56% |
| Q2 2023 | 2023-06-30 | $644,815 | $74,954 | +13.15% |
| Q1 2023 | 2023-03-31 | $602,780 | −$294,820 | −32.85% |
| Q4 2022 | 2022-12-31 | $628,539 | −$22,933 | −3.52% |
| Q3 2022 | 2022-09-30 | $578,203 | −$302,461 | −34.34% |
| Q2 2022 | 2022-06-30 | $569,861 | $136,430 | +31.48% |
| Q1 2022 | 2022-03-31 | $897,600 | $548,485 | +157.11% |
| Q4 2021 | 2021-12-31 | $651,472 | — | — |
| Q3 2021 | 2021-09-30 | $880,664 | — | — |
| Q2 2021 | 2021-06-30 | $433,431 | — | — |
| Q1 2021 | 2021-03-31 | $349,115 | — | — |
SAB Biotherapeutics stock-based compensation trends
Over the last five fiscal years, SAB Biotherapeutics's stock-based compensation increased from $1.3M to $5.2M, a change of $3.9M. The latest reported quarter, Q2 2026, shows $7.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗